Literature DB >> 8680851

Effect of progesterone, testosterone and their 5 alpha-reduced metabolites on GFAP gene expression in type 1 astrocytes.

R C Melcangi1, M A Riva, F Fumagalli, V Magnaghi, G Racagni, L Martini.   

Abstract

Astrocytes possess steroid receptors as well as several enzymes typical of steroid target cells, such as 5 alpha-reductase, which converts testosterone (T) and progesterone (P) into their respective 5 alpha-reduced metabolites, and the 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD). Because of this, it was deemed of interest to analyze whether the original hormones P and T, and their 5 alpha-reduced metabolites dihydrotestosterone (DHT), 5 alpha-androstan-3 alpha, 17 beta-diol (3 alpha-diol), dihydroprogesterone (DHP) and 5 alpha-pregnan-3 alpha-ol-20-one (THP), might exert some effects on the expression of the most typical astrocytic marker, i.e. the glial fibrillary acidic protein (GFAP). Cultures of rat type 1 astrocytes were exposed to the various steroids for 2, 6, and 24 h, and the variations of GFAP mRNA were measured by Northern blot analysis. A significant elevation of GFAP mRNA levels was observed after exposure to either P or DHP; the effect of DHP appeared more promptly (at 2 h) than that of P (at 6 h). This result suggests that the effect of P might be linked to its conversion into DHP; this hypothesis has been confirmed by showing that the addition of finasteride (a specific blocker of the 5 alpha-reductase) is able to completely abolish the effect of P. After exposure to DHP or THP, a decrease of GFAP gene expression was observed at later intervals (24 h). In the case of androgens, T and 3 alpha-diol did not change GFAP expression at any time of exposure, while DHT produced a significant decrease of GFAP mRNA only after 24 h of exposure. Taken together, the data indicate that the 5 alpha-reduced metabolites of P and T may modulate the expression of GFAP in type 1 rat astrocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680851     DOI: 10.1016/0006-8993(95)01302-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Androgens modulate structure and function of the suprachiasmatic nucleus brain clock.

Authors:  Ilia N Karatsoreos; Matthew P Butler; Joseph Lesauter; Rae Silver
Journal:  Endocrinology       Date:  2011-03-01       Impact factor: 4.736

2.  Alterations in glial fibrillary acidic protein (GFAP) mRNA levels in the hamster facial motor nucleus: effects of axotomy and testosterone.

Authors:  K J Jones; N B Kinderman; M M Oblinger
Journal:  Neurochem Res       Date:  1997-11       Impact factor: 3.996

3.  Progesterone pretreatment enhances serotonin-stimulated BDNF gene expression in rat c6 glioma cells through production of 5alpha-reduced neurosteroids.

Authors:  Kyoji Morita; Song Her
Journal:  J Mol Neurosci       Date:  2008-01-25       Impact factor: 3.444

4.  GABA and neuroactive steroid interactions in glia: new roles for old players?

Authors:  Valerio Magnaghi
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

5.  Astrocytes in the rat medial amygdala are responsive to adult androgens.

Authors:  Ryan T Johnson; Amanda Schneider; Lydia L DonCarlos; S Marc Breedlove; Cynthia L Jordan
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

6.  Crosstalk between normal and tumoral brain cells. Effect on sex steroid metabolism.

Authors:  R C Melcangi; I Cavarretta; V Magnaghi; M Ballabio; L Martini; M Motta
Journal:  Endocrine       Date:  1998-02       Impact factor: 3.633

7.  Trichostatin A stimulates steroid 5alpha-reductase gene expression in rat C6 glioma cells via a mechanism involving Sp1 and Sp3 transcription factors.

Authors:  Song Her; Mi-Sook Lee; Kyoji Morita
Journal:  J Mol Neurosci       Date:  2009-09-02       Impact factor: 3.444

8.  The neurosteroid allopregnanolone modulates specific functions in central and peripheral glial cells.

Authors:  Alessandro Faroni; Valerio Magnaghi
Journal:  Front Endocrinol (Lausanne)       Date:  2011-12-28       Impact factor: 5.555

9.  Post-finasteride syndrome: An emerging clinical problem.

Authors:  Silvia Diviccaro; Roberto Cosimo Melcangi; Silvia Giatti
Journal:  Neurobiol Stress       Date:  2019-12-26

Review 10.  Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia.

Authors:  Yu Seob Shin; Keshab Kumar Karna; Bo Ram Choi; Jong Kwan Park
Journal:  World J Mens Health       Date:  2018-08-10       Impact factor: 5.400

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.